Report of the First International Consensus on Standardized Nomenclature of Antinuclear Antibody HEp-2 Cell Patterns 2014-2015

Foundational open-access ICAP nomenclature paper defining nuclear, cytoplasmic, and mitotic HEp-2 patterns with AC codes, competent- vs expert-level reporting, and stating that clear cytoplasmic/mitotic reactivity should still be reported as ANA/HEp-2 IFA positive. Candidate notes: Patterns categorized into nuclear, cytoplasmic, and mitotic groups with anti-cell (AC) codes (AC-1 onward in the initial tree). When clear cytoplasmic or mitotic apparatus reactivity is present, the ANA IIF test is to be reported as positive. Distinguishes competent-level patterns (strongly recommended for reporting) from expert-level patterns. Homogeneous (AC-1) associated with chromatin components such as dsDNA, histones, and/or nucleosomes. Dense fine speckled (AC-2) should be differentiated from homogeneous; DFS is rarely associated with SLE/SjS/SSc and often seen in healthy or non-SARD settings. Disease associations in tables are primarily based on target antigens and are not meant for inclusion as clinical diagnoses on reports alone. Limits noted in the record: First ICAP edition (2015); pattern tree has since expanded (later AC codes). A positive ANA is not a diagnosis. Claims in this record are not verified.

A positive ANA is not a diagnosis. Claims in this record are not verified.

source